These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30701619)

  • 1. Patterns of initial migraine treatment in Denmark: A population-based study.
    Thomsen RW; Szépligeti SK; Xue F; Pedersen L; Sørensen HT; Ehrenstein V
    Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):322-329. PubMed ID: 30701619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment patterns and medication adherence among newly diagnosed patients with migraine: a drug utilisation study.
    Orlando V; Mucherino S; Monetti VM; Trama U; Menditto E
    BMJ Open; 2020 Nov; 10(11):e038972. PubMed ID: 33148742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutically treated comorbidities and associated healthcare costs among triptan users in Switzerland: A pharmacoepidemiological study from a nationwide health insurance database.
    Huber CA; Agosti R; Näpflin M; Blozik E
    Pharmacoepidemiol Drug Saf; 2020 Mar; 29(3):279-287. PubMed ID: 31828875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.
    Tauqeer F; Wood M; Hjorth S; Lupattelli A; Nordeng H
    PLoS One; 2021; 16(8):e0256214. PubMed ID: 34424941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Migraine Prophylaxis and Acute Treatment Patterns Among Commercially Insured Patients in the United States.
    Woolley JM; Bonafede MM; Maiese BA; Lenz RA
    Headache; 2017 Oct; 57(9):1399-1408. PubMed ID: 28842990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
    Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
    J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting.
    Yaldo AZ; Wertz DA; Rupnow MF; Quimbo RM
    Clin Ther; 2008 Dec; 30(12):2452-60. PubMed ID: 19167603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triptans use and overuse: A pharmacoepidemiology study from the French health insurance system database covering 4.1 million people.
    Braunstein D; Donnet A; Pradel V; Sciortino V; Allaria-Lapierre V; Lantéri-Minet M; Micallef J
    Cephalalgia; 2015 Nov; 35(13):1172-80. PubMed ID: 25667299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and determinants of migraine prophylactic medication in the Netherlands.
    Rahimtoola H; Buurma H; Tijssen CC; Leufkens HG; Egberts AC
    Eur J Clin Pharmacol; 2002 May; 58(2):149-55. PubMed ID: 12012149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taking the negative view of current migraine treatments: the unmet needs.
    Tfelt-Hansen P; Olesen J
    CNS Drugs; 2012 May; 26(5):375-82. PubMed ID: 22519921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prophylactic measures and acute treatment of migraine].
    Göbel H; Heinze A; Heinze-Kuhn K
    Schmerz; 2006 Nov; 20(6):541-54; quiz 555-6. PubMed ID: 17048020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a 2-year retrospective cohort study of newly prescribed triptan users in European nationwide practice databases.
    Ng-Mak DS; Chen YT; Ho TW; Stanford B; Roset M
    Cephalalgia; 2012 Sep; 32(12):875-87. PubMed ID: 22833612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study.
    Lipton RB; Munjal S; Buse DC; Bennett A; Fanning KM; Burstein R; Reed ML
    Headache; 2017 Jul; 57(7):1026-1040. PubMed ID: 28603893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of medication overuse headache across classes of treatments for acute migraine.
    Thorlund K; Sun-Edelstein C; Druyts E; Kanters S; Ebrahim S; Bhambri R; Ramos E; Mills EJ; Lanteri-Minet M; Tepper S
    J Headache Pain; 2016 Dec; 17(1):107. PubMed ID: 27882516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and characteristics of patients with migraine in Japan: A retrospective analysis of health insurance claims data.
    Meyers JL; Davis KL; Lenz RA; Sakai F; Xue F
    Cephalalgia; 2019 Oct; 39(12):1518-1534. PubMed ID: 31154807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prophylactic treatment of migraine].
    Igarashi H
    Nihon Rinsho; 2005 Oct; 63(10):1809-14. PubMed ID: 16218395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Patterns of prescription and usage of triptans in Alsace (France): misuse is frequent and avoidable].
    Perearnau P; Vuillemet F; Schick J; Weill G
    Rev Neurol (Paris); 2006 Mar; 162(3):347-57. PubMed ID: 16585890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triptan persistency among newly initiated users in a pharmacy claims database.
    Katić BJ; Rajagopalan S; Ho TW; Chen YT; Hu XH
    Cephalalgia; 2011 Mar; 31(4):488-500. PubMed ID: 20937605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similarities and differences between chronic migraine and episodic migraine.
    Ferrari A; Leone S; Vergoni AV; Bertolini A; Sances G; Coccia CP; Ottani A; Pinetti D; Sternieri E
    Headache; 2007 Jan; 47(1):65-72. PubMed ID: 17355496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilisation of prescription and over-the-counter triptans: a cross-sectional study in Stockholm, Sweden.
    Frisk P; Sporrong SK; Ljunggren G; Wettermark B; von Euler M
    Eur J Clin Pharmacol; 2016 Jun; 72(6):747-54. PubMed ID: 26922586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.